Cetirizine Hydrochloride Market Analysis & Forecast: 2026-2033
The Cetirizine Hydrochloride Market size is anticipated to grow at a CAGR of 7.2% with USD 2.4 Bn in 2026 and is expected to reach USD 3.9 Bn in 2033. The primary drivers are largely defined by the rising prevalence of allergic disorders, including allergic rhinitis, conjunctivitis, and eczema, across all age groups. Some of the other contributing factors include growing over-the-counter availability, increased awareness of non-sedating antihistamines, expanded pediatric formulations, and the adoption of oral solutions and syrups for ease of use. According to the World Allergy Organization, over 400 million people globally suffered from allergic rhinitis, with a notable increase in urban populations experiencing seasonal as well as perennial allergies.
The cetirizine hydrochloride market in the United States is expanding due to the high prevalence of allergic conditions. According to the 2024 National Health Interview Survey, nearly 31.7% of adults reported at least one diagnosed allergic condition (seasonal allergy, eczema, or food allergy) in 2024, with 25.2% specifically experiencing seasonal allergies. This prevalence sustains the demand for cetirizine products, commonly used for relief of seasonal allergic rhinitis as well as chronic urticaria.
In regulatory updates, the U.S. Food and Drug Administration (FDA) issued a drug safety communication in May 2025 requiring revised labeling for cetirizine and levocetirizine to warn about rare but severe pruritus upon abrupt discontinuation after long
In November 2025, Marksans Pharma’s UK subsidiary, Relonchem Limited, received MHRA approval for its anti-allergy medicine, Cetirizine Dihydrochloride 1 mg/ml oral solution. The approval enables marketing in the UK, expanding the company’s allergy treatment portfolio.
The Cetirizine Hydrochloride Market is shifting toward patient-friendly formats such as oral solutions, capsules, and orally disintegrating tablets, as allergy therapy is increasingly used in daily home-care settings. CDC/NCHS reported that 25.7% of U.S. adults had seasonal allergy in 2021, while 18.9% of children had seasonal allergy, thereby supporting the demand for flexible pediatric and adult formulations.
In March 2026, Preferred Pharmaceuticals Inc. received FDA approval for Cetirizine Hydrochloride Oral Solution USP, 5 mg/5 mL (1 mg/mL) in the U.S. This marks it as an approved human prescription drug. It was revised on DailyMed, listing 5 mg/5 mL strength, sugar-free and dye-free grape-flavored syrup, enclosed dosing cup, and use for children aged 2 years and above, thereby improving pediatric dosing convenience.
|
Current Event |
Description and its Impact |
|
U.S. FDA Safety Warning on Cetirizine/Levocetirizine Pruritus |
|
|
U.S. Spot API Price Increase Due to Global Supply Pressure |
|
|
India’s NDCT Rules Amendments (2026)
|
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
On the basis of dosage form, the tablets segment is projected to account for the largest Cetirizine Hydrochloride Market share of 68.5% in 2026. The segment’s growth is owing to the sustained preference for once‑daily 10 mg tablet formulations in allergic rhinitis treatment and broad over‑the‑counter availability backed by regulatory approvals.
In children, 20.6% had a diagnosed seasonal allergy in 2024, underscoring pediatric use of tablet formulations. In addition, allergic rhinitis affects between 10% and 40% of the global population annually, thereby underscoring the broad target patient base for tablet antihistamines.
In October 2024, Indoco Remedies Limited received the final USFDA approval for its Abbreviated New Drug Application (ANDA) for Cetirizine Hydrochloride Tablets USP, 10 mg (OTC). The approval enables Indoco to market a generic equivalent of Zyrtec Allergy Tablets, 10 mg of Johnson & Johnson Consumer Inc. This is enhancing access to affordable allergy relief options in key global markets.
To learn more about this report, Request Free Sample
On the basis of application, the allergic rhinitis segment lead with a major 61.5% share in 2026. The segment’s growth is owing to the to the high prevalence of allergic conditions and the widespread preference for second‑generation antihistamine drugs like cetirizine.
According to the U.S. CDC National Ambulatory Medical Care Survey, approximately 4.1 million physician office visits in 2025 were attributed primarily to allergic rhinitis, reflecting the high clinical engagement and frequent recommendation of cetirizine tablets.
In addition, allergic rhinitis affects an estimated 15% of the U.S. population which is about 50 million individuals. This underscores its large patient base as well as a substantial demand for antihistamine therapies globally.
To learn more about this report, Request Free Sample
The North America region accounts for 36.2% of the market share in 2026. The region’s growth is owing to by the increasing prevalence of allergic conditions, such as seasonal and perennial allergic rhinitis, combined with strong OTC accessibility of second‑generation antihistamines. In addition, heightened awareness and adoption of convenient dosage forms, including chewables and gummies, are fueling market expansion.
A Phase 1 clinical study evaluating the bioavailability of a 10 mg cetirizine HCl gummy formulation is registered with ClinicalTrials.gov, with an estimated completion in September 2025, indicating ongoing formulation development efforts. Additionally, regulatory records show a new OTC chewable cetirizine hydrochloride label was approved effective April 2026 in the FDA database, reflecting evolving product approvals within the segment.
In February 2024, Harrow, Inc. entered an exclusive licensing agreement with Apotex Inc. to market and distribute several ophthalmic products in Canada, including pursuing approval for ZERVIATE (cetirizine ophthalmic solution 0.24%).
Asia Pacific is expected to witness strong growth in Cetirizine Hydrochloride Market over the forecast period. The region’s growth is owing to the increasing prevalence of allergic disorders such as allergic rhinitis and conjunctivitis, alongside rising consumer awareness of over-the-counter antihistamine options supported by government health initiatives.
In India, the National Pharmaceutical Pricing Authority (NPPA) computed and capped the retail price of cetirizine hydrochloride ophthalmic solution (0.24% w/v) at Rs 14.42 per ml for 5 ml packs in early 2026 under its Drug Price Control Order framework, highlighting active government pricing oversight and affordability controls in key formulations.
On the clinical trial front, an ongoing randomized study (NCT07236372) is investigating higher cetirizine dosing for symptom relief in allergic conditions, indicating continued research into optimized use.
In December 2024, Nicox SA announced the first commercial sale of ZERVIATE (cetirizine ophthalmic solution) 0.24% in China through its exclusive partner, Ocumension Therapeutics. The product was approved in China in September 2024 and is indicated for ocular itching associated with allergic conjunctivitis.
The Cetirizine Hydrochloride Market in the United States is experiencing substantial growth. The growth is owing to increasing allergy prevalence and expanded generic availability.
According to the U.S. Food and Drug Administration data, an estimated 26.8 million prescriptions for cetirizine and levocetirizine were dispensed from U.S. outpatient pharmacies in 2022, with 65% linked to OTC use, thereby reflecting the sustained high utilization.
In February 2026, Aurohealth LLC received the FDA approval for Cetirizine Hydrochloride as an over-the-counter (OTC) human drug in the U.S. This marks it as an officially approved human OTC medication.
The Cetirizine Hydrochloride Market in China is experiencing substantial growth. The growth is owing to the increasing prevalence of allergic conditions like allergic rhinitis. The epidemiological studies show that it affects an estimated 18% of the Chinese population and has risen substantially over recent decades.
The regulatory developments continue to propel the market expansion. In August 2025, the National Medical Products Administration (NMPA) granted a quality and efficacy consistency evaluation approval for the 10 mg cetirizine hydrochloride tablets manufactured by Xinhua Pharmaceutical. This made it the first OTC cetirizine product in China to achieve this regulatory milestone, thereby enhancing generic confidence and competitive positioning.
Some of the major key players in Cetirizine Hydrochloride are Johnson and Johnson, Mylan, Inc., Nicox S.A., Strides Shasun, Apotex, Inc., Teva UK Limited, Aurobindo Pharma Limited, Jubilant Life Sciences, Tris Pharma, Inc., and Cipla Ltd.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 2.4 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.2% | 2033 Value Projection: | USD 3.9 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Johnson and Johnson, Mylan, Inc., Nicox S.A., Strides Shasun, Apotex, Inc., Teva UK Limited, Aurobindo Pharma Limited, Jubilant Life Sciences, Tris Pharma, Inc., and Cipla Ltd. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Vipul Patil is a dynamic management consultant with 6 years of dedicated experience in the pharmaceutical industry. Known for his analytical acumen and strategic insight, Vipul has successfully partnered with pharmaceutical companies to enhance operational efficiency, cross broader expansion, and navigate the complexities of distribution in markets with high revenue potential.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
